Abstract
Metastatic castration-resistant prostate cancer is a severe disease. Recently, however, its therapy has been significantly enriched adding novel treatment options extending patient overall survival.
Abirateron acetate belongs to the group of agents directed primarily towards androgen receptor blockade. Based on two important clinical studies, COU-AA-302 and COU-AA-301, it has become a reliable pillar of the therapy of patients with metastatic castration-resistant prostate cancer, both prior to chemotherapy and after previous cytotoxic treatment.
The overview article describes the current position of abirateron acetate in the treatment of this malignancy.